Travel & financial grants

The Assistance Fund

The Assistance Fund Cystic Fibrosis Copay Assistance Program provides financial assistance for out-of-pocket costs, such as copays, deductibles, and coinsurance, for prescribed FDA-approved treatments for cystic fibrosis. Eligible patients must be U.S. citizens or permanent residents, diagnosed with the disease, prescribed an FDA-approved treatment, have prescription coverage, and meet financial eligibility criteria. The program is currently accepting requests to join its enrollment waitlist.

The Assistance Fund

The Assistance Fund's Hemophilia Financial Assistance Program offers grants to U.S. citizens or permanent residents with hemophilia, covering costs like prescription drugs, health insurance premiums, therapy administration, genetic testing, and ground travel to treatment centers. Applicants must be diagnosed with hemophilia, prescribed an FDA-approved treatment, have prescription coverage, and meet financial eligibility criteria based on household income and size. The program is currently accepting waitlist applications.

The Assistance Fund

The Hemophilia Financial Assistance Program, offered by The Assistance Fund, provides financial assistance to U.S. citizens or permanent residents diagnosed with hemophilia who are prescribed an FDA-approved treatment and have prescription coverage. It covers out-of-pocket costs such as prescription drugs, health insurance premiums, therapy administration, genetic testing, and ground travel to treatment centers. Applicants must meet financial eligibility criteria based on household income and size.

The Assistance Fund

The Uveitis Copay Assistance Program, sponsored by The Assistance Fund, provides financial assistance for out-of-pocket costs such as copays, deductibles, and coinsurance for FDA-approved uveitis treatments. Eligibility requires U.S. citizenship or permanent residency, a uveitis diagnosis, prescription coverage, and meeting financial criteria based on household income and size. The program is currently accepting patients to its waitlist.

The Assistance Fund

The Uveitis Copay Assistance Program, sponsored by The Assistance Fund, provides financial assistance for out-of-pocket costs related to prescribed FDA-approved uveitis treatments, including copays, deductibles, and coinsurance. To qualify, patients must be U.S. citizens or permanent residents diagnosed with uveitis, prescribed an FDA-approved treatment, have prescription coverage, and meet financial eligibility criteria based on household income and size. The program is currently on a waitlist.

The Assistance Fund

The Assistance Fund's Chronic Granulomatous Disease (CGD) program offers financial assistance for copays, coinsurance, deductibles, health insurance premiums, and other medical expenses related to FDA-approved treatments for CGD. This support is for commercially insured or Medicare/Medicaid patients residing in the US and Puerto Rico who are prescribed specific medications and meet financial eligibility criteria.

The Assistance Fund

The Assistance Fund: Epidermolysis Bullosa program offers financial support for U.S. citizens or permanent residents diagnosed with epidermolysis bullosa. It covers copays, coinsurance, and deductibles for FDA-approved treatments, health insurance premiums, and incidental medical expenses. Applicants must be commercially insured or on Medicare/Medicaid and meet income criteria to qualify.

The Assistance Fund

The Assistance Fund: Gaucher Disease program offers financial assistance for copays, coinsurance, deductibles, health insurance premiums, and incidental medical expenses related to FDA-approved treatments for Gaucher Disease. It is available to commercially insured, Medicare/Medicaid patients residing in the US and Puerto Rico who meet financial need-based criteria.

The Assistance Fund

The Assistance Fund: Gaucher Disease program offers financial assistance for copays, coinsurance, deductibles, health insurance premiums, and incidental medical expenses related to FDA-approved treatments for Gaucher Disease. Eligible patients must be residents of the US or Puerto Rico, have commercial insurance, Medicare, or Medicaid, and meet financial need criteria. The program supports patients prescribed drugs such as Cerezyme, Vpriv, Zavesca, Elelyso, Cerdelga, and Miglustat, and may also cover off-label drugs.

The Assistance Fund

The Assistance Fund: Immunoglobulin A Nephropathy (IgAN) program provides financial assistance for individuals prescribed FDA-approved treatments like Tarpeyo, Filspari, or Fabhalta. It covers copays, coinsurance, deductibles, health insurance premiums, and other eligible incidental medical expenses. Eligibility is for commercially insured, Medicare, or Medicaid patients residing in the US and Puerto Rico, based on income guidelines.

The Assistance Fund

The Assistance Fund: Multiple Sclerosis provides financial aid for copays, coinsurance, deductibles, health insurance premiums, and incidental medical expenses. It is available to commercially insured or Medicare/Medicaid patients in the US and Puerto Rico with a primary diagnosis of multiple sclerosis, and is needs-based.

The Assistance Fund

The Assistance Fund: Narcolepsy provides financial assistance for copays, deductibles, coinsurance, health insurance premiums, and incidental medical expenses for FDA-approved narcolepsy treatments, including off-label drugs. Eligible patients must be U.S. citizens or permanent residents with a narcolepsy diagnosis and insurance, and demonstrate financial need.

The Assistance Fund

The Assistance Fund: Pulmonary Hypertension provides financial support for copays, coinsurance, deductibles, health insurance premiums, and incidental medical expenses related to FDA-approved pulmonary hypertension treatments. It is available to commercially insured, Medicare/Medicaid patients residing in the US and Puerto Rico who meet financial need criteria.

The Assistance Fund

The Assistance Fund: Rheumatoid Arthritis program provides financial support for copays, coinsurance, deductibles, health insurance premiums, and incidental medical expenses for FDA-approved rheumatoid arthritis treatments. Eligibility requires patients to be residents of the US or Puerto Rico, have commercial insurance or Medicare/Medicaid, and meet specific income requirements. However, the program is currently not funded.

Merck

The Assistance Fund

The Thrombocytopenia Financial Assistance Program offers financial assistance for out-of-pocket costs, including prescription drugs, health insurance premiums, therapy administration, and travel expenses to treatment centers or specialists (ground transportation, air travel, meals, hotel stays). It is for U.S. citizens or permanent residents diagnosed with Thrombocytopenia, who are prescribed an FDA-approved treatment, have prescription coverage, and meet financial eligibility criteria based on household income and size. The program is currently accepting waitlist applications.

This page is a compilation of various transportation assistance programs offered by different organizations for pediatric cancer patients, rather than detailing a single grant provided under the name 'Transportation Resources for Pediatric Cancer Patients'. Each listed program has its own specific coverage, eligibility criteria, and application process.

OncoLink

This OncoLink resource page, 'Transportation Resources for Pediatric Cancer Patients', compiles a list of external organizations that offer travel assistance. It outlines various programs that help with costs such as flights, gas, lodging, and meals for pediatric cancer patients and their families. Eligibility and application details are specific to each listed organization, not OncoLink itself.

Novartis Oncology

This is the Novartis Oncology Universal Co-pay Program, offering financial assistance for out-of-pocket medication costs for eligible Novartis Oncology products like Tykerb. It is available to US residents (excluding Massachusetts, with additional criteria for California) who have commercial insurance and are not enrolled in government healthcare programs. The program covers up to $30,000 per calendar year for medication co-pays, after the patient pays an initial $10 co-pay per 30-day supply.

UCB Canada Inc.

The UCB Cares Patient Support Program provides support and helpful resources to patients prescribed CIMZIA® or BIMZELX® and their physicians throughout their treatment journey. The program aims to assist with various aspects of managing these conditions.

United Therapeutics

The United Therapeutics Patient Support Programs, primarily through United Therapeutics Cares, offer personalized education, insurance navigation, and general financial support options for out-of-pocket treatment costs. The provided content does not explicitly mention coverage for travel expenses such as flights, hotel, or gas.